Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Spanish vaccination calendar since 2007. The new nonavalent HPV vaccine (9vHPV), approved in Europe in 20...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2019-08-01
|
| Rangatū: | Human Vaccines & Immunotherapeutics |
| Ngā marau: | |
| Urunga tuihono: | http://dx.doi.org/10.1080/21645515.2018.1560770 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|